Mike Whitney

AureoGen Biosciences (United States)

Papers

1

Total Citations

24

H-Index

1

About

Dr. Mike Whitney is a biochemist whose work has significantly advanced the understanding of viral protease mechanisms, particularly in the context of Hepatitis C virus (HCV) drug discovery. His research focuses on the development of high-throughput screening methodologies and the characterization of enzyme-inhibitor interactions. Dr. Whitney’s most notable contribution is his collaborative work on a pioneering screening program that identified inhibitors of the HCV NS2/3 cis-cleaving protease, a challenging target due to its auto-proteolytic nature. This study, published in 2002 and garnering 24 citations, provided a foundational framework for subsequent antiviral research by demonstrating a viable approach to targeting this elusive enzyme. The impact of this work extends beyond HCV, informing strategies for protease inhibitor development across virology. Dr. Whitney’s contributions are recognized for bridging the gap between basic enzymology and applied therapeutic discovery, making him a key figure in the early efforts to combat HCV through targeted protease inhibition.

Research Focus

Key Achievements

1
H-Index
1
Papers
24
Total Citations
24
Avg Citations/Paper
🏆 Most Cited Paper
A Collaborative Screening Program for the Discovery of Inhibitors of HCV NS2/3 cis-Cleaving Protease Activity
24 citations · 2002
📈 Most Prolific Year: 2002 (1 Papers)
🤝 Key Collaborators: 8
🏛 Institutions: AureoGen Biosciences (United States)

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 10 days ago